Key Highlights
- Pharmaceutical giant Eli Lilly is pursuing an acquisition of Kelonia Therapeutics valued at more than $2 billion, according to Wall Street Journal sources
- An announcement may come as soon as Monday, with additional performance-based compensation included
- Kelonia focuses on developing innovative CAR-T cancer treatments targeting multiple myeloma
- The Massachusetts-based biotechnology firm has secured approximately $60 million in funding and held a valuation exceeding $100 million in 2022
- This acquisition would strengthen Lilly’s cancer treatment portfolio while diversifying beyond its successful metabolic disease franchise
Eli Lilly has entered late-stage negotiations to purchase Boston-headquartered Kelonia Therapeutics in a transaction exceeding $2 billion, per a Wall Street Journal article released Sunday. While an announcement could arrive as soon as Monday, the discussions remain subject to potential collapse.
The agreement may feature supplementary compensation contingent upon Kelonia achieving specific clinical and regulatory benchmarks, according to sources briefed on the discussions cited by the Journal.
LLY shares climbed approximately 2.55% following the disclosure.
Kelonia operates as a clinical-stage biotechnology company specializing in CAR-T cellular therapies — innovative treatments that modify a patient’s immune system to target and eliminate malignant cells.
The firm concentrates primarily on multiple myeloma, a blood cancer affecting plasma cells. Its technological approach streamlines CAR-T administration by eliminating the requirement for preparatory chemotherapy and reducing the intensive cell production processes traditionally associated with these treatments.
This represents a significant advancement within the CAR-T sector, where operational complexities have historically limited broader adoption.
Kelonia has secured financing totaling just under $60 million. The company’s most recent valuation stood slightly above $100 million in 2022 — indicating the reported acquisition price represents a substantial premium.
Eli Lilly and Kelonia have not provided statements to Reuters’ inquiries made outside standard operating hours.
Expanding the Oncology Platform
Lilly maintains an established presence in cancer therapeutics. Its current oncology portfolio features Jaypirca and Verzenio for breast cancer treatment, alongside multiple investigational compounds.
Acquiring Kelonia would extend Lilly’s capabilities in hematologic malignancies, representing one of oncology’s most dynamic growth sectors.
The transaction aligns with recent activity. Lilly has pursued multiple strategic acquisitions, supported by substantial revenue generation from blockbuster treatments Zepbound for weight management and Mounjaro for diabetes.
This February, Lilly announced plans to purchase Orna Therapeutics in a deal valued at up to $2.4 billion. Kelonia would represent another substantial investment during a concentrated timeframe.
Strategic Diversification Efforts
Lilly has openly communicated its diversification objectives. The pharmaceutical company has been extending into inflammatory bowel conditions, ophthalmic disorders, oncology, and genetic modification platforms through strategic purchases and collaborative arrangements.
CAR-T technology aligns directly with this direction. The therapeutic approach has demonstrated substantial efficacy against blood-based malignancies, with multiple products already receiving regulatory approval — though production complexity and economic accessibility remain industry-wide challenges requiring solutions.
Kelonia’s streamlined methodology represents its primary appeal. The ability to generate positive outcomes while reducing operational barriers creates meaningful competitive differentiation worthy of premium valuation.
Lilly has offered no official confirmation regarding the transaction. The Wall Street Journal noted negotiations could still terminate before any public announcement.
LLY shares traded up roughly 2.55% in response to the disclosure.
